Maintenance Notice

Due to necessary scheduled maintenance, the JMIR Publications website will be unavailable from Wednesday, July 01, 2020 at 8:00 PM to 10:00 PM EST. We apologize in advance for any inconvenience this may cause you.

Who will be affected?

Accepted for/Published in: JMIR Formative Research

Date Submitted: Feb 10, 2024
Open Peer Review Period: Feb 12, 2024 - Apr 8, 2024
Date Accepted: Apr 4, 2024
(closed for review but you can still tweet)

The final, peer-reviewed published version of this preprint can be found here:

Reliability of a Smartphone App to Objectively Monitor Performance Outcomes in Degenerative Cervical Myelopathy: Observational Study

Yanez Touzet A, Houhou T, Rahic Z, Kolias A, Yordanov S, Anderson DB, Laufer I, Li M, Grahovac G, Kotter MRN, Davies BM, MoveMed Ltd

Reliability of a Smartphone App to Objectively Monitor Performance Outcomes in Degenerative Cervical Myelopathy: Observational Study

JMIR Form Res 2024;8:e56889

DOI: 10.2196/56889

PMID: 38787602

PMCID: 11161705

Reliability of a smartphone app to objectively monitor performance outcomes in degenerative cervical myelopathy: an observational study

  • Alvaro Yanez Touzet; 
  • Tatiana Houhou; 
  • Zerina Rahic; 
  • Angelos Kolias; 
  • Stefan Yordanov; 
  • David B Anderson; 
  • Ilya Laufer; 
  • Maggie Li; 
  • Gordan Grahovac; 
  • Mark R N Kotter; 
  • Benjamin M Davies; 
  • MoveMed Ltd

ABSTRACT

Background:

Developing new clinical measures for degenerative cervical myelopathy (DCM) is an AO Spine RECODE-DCM Research priority. Difficulties detecting DCM, and change in DCM, cause diagnostic and treatment delays in clinical settings and heightened costs in clinical trials due to elevated recruitment targets. Digital outcome measures can tackle these challenges due to their ability to measure disease remotely, repeatedly, and more economically.

Objective:

To assess the reliability of the MoveMed battery of performance outcome measures.

Methods:

Design: Prospective observational study. Setting: Decentralised secondary care in England, United Kingdom. Participants: Seven adults aged 59.5 (SD 12.4) who live with degenerative cervical myelopathy (DCM) and possess an approved smartphone. Primary and secondary outcome measures: The primary outcome was to determine the test-retest reliability of the MoveMed performance outcomes using the intra-class correlation of agreement (ICCagreement). The secondary outcome was to determine the measurement error of the MoveMed performance outcomes using both the standard error of agreement of the mean (SEMagreement) and the smallest detectable change of agreement (SDCagreement). Criteria from the Consensus-based Standards for the selection of health Measurement Instruments (COSMIN) manual were used to determine adequate reliability (i.e., ICCagreement ≥ 0.7) and risk of bias. Disease stability was controlled for using two minimum clinically important difference (MCID) thresholds obtained from the literature on the patient-derived modified Japanese Orthopaedic Association (P-mJOA): namely, MCID ≤1 point and MCID ≤2 points.

Results:

All tests demonstrated moderate-to-excellent test-retest coefficients and low measurement errors. In the MCID ≤1 group, ICCagreement values ranged from: 0.84–0.94 in the Fast Tap Test, 0.89–0.95 in the Hold Test, 0.95 in the Typing Test, and 0.98 in the Stand and Walk Test. SEMagreement values ranged from ±1 tap, ±1–3% stability score points, ±0.06 keys per second, and ±10 steps per inute, respectively. SDCagreement values were ±3 taps, ±4–7% stability score points, ±0.2 keys per second, and ±27 steps per minute. In the MCID ≤2 group, ICCagreement values ranged from: 0.61–0.91, 0.75–0.77, 0.98, and 0.62, respectively; SEMagreement values from: ±1 tap, ±2–4% stability score points, ±0.06 keys per second, and ±10 steps per minute; and SDCagreement values from: ±3–7 taps, ±7–10% stability score points, ±0.2 keys per second, and ±27 steps per minute. Furthermore, the Fast Tap, Hold, and Typing Tests obtained sufficient ratings (ICCagreement ≥ 0.7) in both MCID≤1 and MCID≤2 groups. No risk of bias factors from the COSMIN Risk of Bias checklist were recorded. Overall, ‘very good’ quality evidence of sufficient reliability was found for the MoveMed battery in DCM.

Conclusions:

Criteria from COSMIN provide ‘very good’ quality evidence of the reliability of the MoveMed tests in an adult population living with DCM.


 Citation

Please cite as:

Yanez Touzet A, Houhou T, Rahic Z, Kolias A, Yordanov S, Anderson DB, Laufer I, Li M, Grahovac G, Kotter MRN, Davies BM, MoveMed Ltd

Reliability of a Smartphone App to Objectively Monitor Performance Outcomes in Degenerative Cervical Myelopathy: Observational Study

JMIR Form Res 2024;8:e56889

DOI: 10.2196/56889

PMID: 38787602

PMCID: 11161705

Download PDF


Request queued. Please wait while the file is being generated. It may take some time.

© The authors. All rights reserved. This is a privileged document currently under peer-review/community review (or an accepted/rejected manuscript). Authors have provided JMIR Publications with an exclusive license to publish this preprint on it's website for review and ahead-of-print citation purposes only. While the final peer-reviewed paper may be licensed under a cc-by license on publication, at this stage authors and publisher expressively prohibit redistribution of this draft paper other than for review purposes.